Logo

Boehringer Ingelheim's Ofev (nintedanib) Receives Health Canada's Approval as the First Therapy to Treat SSc-ILD in Canada

Share this

Boehringer Ingelheim's Ofev (nintedanib) Receives Health Canada's Approval as the First Therapy to Treat SSc-ILD in Canada

Shots:

  • Health Canada approved Ofev (nintedanib) as the first and only treatment- indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease
  • The approval is based P-III SENSCIS study assessing Ofev vs PBO in 576 patients with SSc-ILD across 32 countries including Canada- resulted in slowing loss of pulmonary function by 44% as measured by FVC over 52wks.
  • Ofev is a tyrosine kinase inhibitor- currently approved in 70+ countries including Canada for patients with idiopathic pulmonary fibrosis (IPF) and received FDA’s for approval for treating SSc-ILD

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: Top Employers Institute


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions